Advertisement
Advertisement

RCKT

RCKT logo

Rocket Pharmaceuticals, Inc. Common Stock

3.02
USD
Sponsored
-0.05
-1.63%
Jun 01, 15:59 UTC -4
Closed
exchange

After-Market

3.05

+0.03
+0.96%

RCKT Earnings Reports

Positive Surprise Ratio

RCKT beat 25 of 40 last estimates.

63%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
$0.10
Implied change from Q1 26 (Revenue/ EPS)
--
/
-123.81%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-116.95%

Rocket Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On May 07, 2026, RCKT reported earnings of -0.42 USD per share (EPS) for Q1 26, missing the estimate of -0.41 USD, resulting in a -1.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.09% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of 0.10 USD, with revenue projected to reach -- USD, implying an decrease of -123.81% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Greenwich LifeSciences, Inc.
Report Date
Jun 01, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.57
Surprise
-77.70%
logo
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
logo
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
logo
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-
Actual
-$4.76
Surprise
-
logo
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
logo
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
logo
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
logo
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
logo
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
logo
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
For Q1 2026, Rocket Pharmaceuticals, Inc. Common Stock reported EPS of -$0.42, missing estimates by -1.18%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.09%, changed from $3.67 before the earnings release to $3.63 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 10 analysts, Rocket Pharmaceuticals, Inc. Common Stock is expected to report EPS of $0.10 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement